IMCR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 107563 min ago

@ $71.91

Išleistas: 14 vas. 2024 @ 22:47

Grąža: -17.57%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: -2.49 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 16:31):

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases...

Stats
Šios dienos apimtis	4 400.00
Vidutinė apimtis	512 688
Rinkos kapitalizacija	2.95B
EPS	$0 ( 2024-02-28 )
Kita pelno data	( $-0.320 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-41.74
ATR14	$0.0510 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	St Leger Tina Amber	Sell	4 375	Employee Share Option (Right to Buy)
2024-04-01	St Leger Tina Amber	Buy	4 375	Ordinary Shares
2024-04-01	St Leger Tina Amber	Sell	4 375	Ordinary Shares
2024-02-28	Berman David M	Sell	36 509	Employee Share Option (Right to Buy)
2024-02-28	Berman David M	Buy	36 509	Ordinary Shares

INSIDER POWER
-75.94
Last 63 transactions
Buy: 607 651 \| Sell: 4 752 433

Tūris Koreliacija

Ilgas: 0.49 (neutral)

Trumpas: 0.68 (moderate)

Signal:(74.516) Neutral

Immunocore Holdings plc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
AMRB	0.859
LWAC	0.837
MMAC	0.835

10 Labiausiai neigiamai susiję koreliacijos
SVAC	-0.83
TLGT	-0.821

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Immunocore Holdings plc Koreliacija - Valiuta/Žaliavos

0.62
( weak )

0.55
( weak )

0.00
( neutral )

0.62
( weak )

-0.38
( neutral )

-0.56
( weak negative )

Immunocore Holdings plc Finansinės ataskaitos

Annual	2023
Pajamos:	$249.43M
Bruto pelnas:	$248.39M (99.58 %)
EPS:	$-0.00110

FY	2023
Pajamos:	$249.43M
Bruto pelnas:	$248.39M (99.58 %)
EPS:	$-0.00110

FY	2022
Pajamos:	$143.74M
Bruto pelnas:	$143.28M (99.68 %)
EPS:	$-0.900

FY	2021
Pajamos:	$26.52M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-3.10

Financial Reports:

No articles found.

Immunocore Holdings plc

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.